Home » CombinatoRx Begins Phase IIa Study of CRx-191 in Psoriasis
CombinatoRx Begins Phase IIa Study of CRx-191 in Psoriasis
CombinatoRx has begun dosing in a Phase IIa trial of CRx-191 in psoriasis patients.
CRx-191 is a topical synergistic combination drug candidate for psoriasis and other steroid-responsive dermatoses. The trial will evaluate the efficacy, safety and tolerability of CRx-191 compared with each of its components and placebo in subjects with psoriasis.
The 12-day, single-center, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of CRx-191 in reducing psoriatic infiltrate band thickness. Approximately 20 subjects will be enrolled.
Endpoints include reduction from baseline in psoriatic infiltrate as measured by ultrasound at day 12, CombinatoRx said.
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May